Guardant DNA blood test detects 83% of colorectal tumors in trial. Colorectal-cancer test results disappoint investors. According to a Guardant statement issued late Thursday, the test correctly identified the presence of cancer or precancer 83% of the time, with a 10% false positivity rate. T the stock dropped 31%. Exact Sciences Corp., which makes a more accurate test called Cologuard that searches for symptoms of colon cancer in stool samples, surged more than 26%.
“Over 49 million eligible people in the U.S. remain unscreened for colorectal cancer. We are confident that a high-sensitivity blood test can play a critical role in improving screening adherence rates by offering an accurate and convenient blood test to those reluctant to get screened,” said AmirAli Talasaz, Guardant Health co-CEO. “These results demonstrate, for the first time, that a blood test can indeed achieve high-sensitivity detection for colorectal cancer, a disease that was thought to be difficult to detect in blood. And as groundbreaking as these results are, colorectal cancer is just the beginning. Fueled by this success, we will expand this test to detecting many other cancer types, including lung cancer, the leading cause of death from cancer.”
Instead of invasive treatments like colonoscopies, it may be possible to identify cancer with a blood draw, commonly known as a liquid biopsy. Health fans are excited about the news.
“We’ve been working steadily for many years to reach this milestone,” Guardant Health co-CEO AmirAli Talasaz said in an investor call on Thursday. “As of today, blood-based CRC screening is a reality.”
Celebrity News Update- Premier Jewelry designer and manufacturer fashion house ParisJewelry.com has started manufacturing a new custom line of celebrity jewelry designs with 30% Off and Free Shipping. Replenish Your Body- Refilter Your Health with OrganicGreek.com Vitamin Bottles, Vitamins and Herbs.
